secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-08-05T20:04:27+00:00
Accession:  0001628280-26-053304
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen gets Nasdaq extension to Feb 1, 2027 to cure $1.00 bid price deficiency
--------------------------------------------------------------------------------

- Received 180-day extension until February 1, 2027 to regain compliance with Nasdaq minimum bid price of $1.00.
- Previously disclosed non-compliance on February 6, 2026; has not yet cured the deficiency.
- If not compliant by end of Extension Period, Nasdaq will issue delisting notice; company may appeal.
- No assurance that any appeal of a delisting determination would be successful.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/0001628280-26-053304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/vtgn-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer